Prospects for molecular staging of non-small-cell lung cancer from genomic alterations

Sandra C. Tomaszek, Marianne Huebner, Dennis A. Wigle

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Genomic technology continues to advance, and data derived from non-small-cell lung cancer (NSCLC) tumor specimens in conjunction with clinical information are accumulating at an exponential rate. Application of this information to clinical practice for the treatment of patients with NSCLC lags behind the promise of individualized patient management based on genomic medicine. Testing treatment decisions based on genomic information in cancer clinical trials is only now being addressed. How best to incorporate the myriad of potentially available molecular diagnostics into treatment algorithms is not yet clear. Many hurdles and much work remain for the development of true, individualized treatment strategies for NSCLC based on molecular staging. Here we review some of the successes, frustrations and obstacles that exist to further progress in the field.

Original languageEnglish (US)
Pages (from-to)499-508
Number of pages10
JournalExpert Review of Respiratory Medicine
Issue number4
StatePublished - Aug 2010


  • DNA sequencing
  • EGFR
  • SNP
  • biomarkers
  • clinical trials
  • gene expression
  • methylation
  • microRNA
  • mutation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Prospects for molecular staging of non-small-cell lung cancer from genomic alterations'. Together they form a unique fingerprint.

Cite this